Email BrainsGate
We would be happy to provide further information. Please fill the form below and we will get back to you shortly.
|
September 25, 2008
BrainsGate launches ImPACT-24
ImPACT-24 is a randomized, sham-controlled, double blind study to test the safety and efficacy of BrainsGate's ISS for treatment of acute ischemic stroke victims in a 24 hour window > full story
August 13, 2008
BrainsGate raises $27.5m
This is the first investment in Israel in over a year by Johnson & Johnson's VC arm.
by Gali Weinreb > full story
|
Login
